Press Releases 08.15.2024 Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma 12.07.2022 Aarvik Therapeutics Announces a Global Novel Payload Agreement with NJ Bio, Inc. 08.19.2022 Aarvik Therapeutics Announces Validation of Novel Tetravalent Antibody Platform 12.23.2021 Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform 09.23.2021 Aarvik Therapeutics Appoints Dr. Richard Scheller to Board of Directors, Dr. Melissa Starovasnik to Scientific Advisory Board, and Announces Scientific Team 08.23.2021 Aarvik Therapeutics (formerly Aarkus Therapeutics) Announces Successful Series Seed Financing 06.23.2021 Aarvik Therapeutics Launches with a Novel Modular Antibody Technology Platform
